Shares of Egalet Corp. (NASDAQ:EGLT) rose 9.6% during trading on Wednesday . The stock traded as high as $7.83 and last traded at $7.73, with a volume of 111,384 shares changing hands. The stock had previously closed at $7.05.

EGLT has been the topic of several research analyst reports. Cantor Fitzgerald reissued a “buy” rating on shares of Egalet Corp. in a research note on Tuesday, June 28th. Zacks Investment Research lowered shares of Egalet Corp. from a “hold” rating to a “sell” rating in a report on Thursday, May 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. Egalet Corp. presently has a consensus rating of “Hold” and an average target price of $15.88.

The firm’s 50-day moving average is $5.87 and its 200 day moving average is $6.57. The firm’s market cap is $186.35 million.

Egalet Corp. (NASDAQ:EGLT) last issued its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.15. During the same period last year, the business earned ($1.03) EPS. The business had revenue of $3.45 million for the quarter, compared to analyst estimates of $3.83 million. The firm’s quarterly revenue was up 259.4% on a year-over-year basis. Equities research analysts predict that Egalet Corp. will post ($3.12) EPS for the current fiscal year.

In other news, CFO Stan Musial sold 13,480 shares of the business’s stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $5.06, for a total value of $68,208.80. Following the completion of the transaction, the chief financial officer now directly owns 84,940 shares in the company, valued at approximately $429,796.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert S. Radie sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 6th. The shares were sold at an average price of $5.01, for a total transaction of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 259,900 shares of the company’s stock, valued at $1,302,099. The disclosure for this sale can be found here.

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.